Highlights

• Neurotech shares rose 7.14% to AUD 0.015 on 2 July 2026 following a favourable patent update.

• The USPTO issued Notices of Allowance for two U.S. patent applications covering NTI164.

• The proposed patents relate to reducing neuroinflammation and treating autism spectrum disorder.

• Once granted, the patents are expected to protect NTI164 intellectual property through to 2042.

• NTI164 continues to advance through Phase 3 clinical development for paediatric autism spectrum disorder.

Shares of Neurotech International Ltd (ASX:NTI) climbed 7.14% to AUD 0.015 during the morning session on 2 July 2026 after the company announced a significant development in its United States intellectual property strategy. The positive share price reaction followed confirmation that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two U.S. patent applications covering the company's lead drug candidate, NTI164. Despite today's gain, the stock remains 25.00% lower over the past year, highlighting that investors continue to monitor both the company's clinical and intellectual property milestones.

Neurotech International is a clinical-stage biopharmaceutical company focused on developing therapies for paediatric neurological disorders. Its lead product candidate, NTI164, is a proprietary oral cannabinoid-based formulation being developed primarily for children diagnosed with autism spectrum disorder (ASD). Beyond autism, the company has also undertaken clinical development across conditions including Rett Syndrome and PANDAS/PANS. Neurotech's strategy combines clinical development with intellectual property expansion to support the long-term commercial potential of its pipeline.

USPTO Update Advances Neurotech's Intellectual Property Strategy

The latest announcement centres on two U.S. patent applications that have now received Notices of Allowance from the USPTO. While the patents are not yet formally granted, the Notices indicate that the applications have satisfied the patentability requirements established by the U.S. patent office. Subject to completion of the remaining administrative processes, the company expects both patents to be issued within the coming months.

The two applications, U.S. Patent Application No. 18/698,605 and U.S. Patent Application No. 19/335,945, are both titled "Compositions and Methods for Treating Neurological Disorders." They relate to important therapeutic applications of NTI164 and form part of Neurotech's broader strategy to strengthen protection around its lead pharmaceutical asset.

According to the company, once these patents are granted, they are expected to provide intellectual property protection for NTI164 in the United States through 2042, subject to the payment of applicable maintenance fees.

Patent Applications Cover Two Key Therapeutic Areas

The newly allowed patent applications focus on separate aspects of NTI164's therapeutic use.

One application covers methods of reducing neuroinflammation using NTI164. Neuroinflammation has been identified as an important biological process associated with several neurological and neurodevelopmental conditions, making this area of protection relevant to the company's broader research and development strategy.

The second application specifically relates to methods of treating autism spectrum disorder (ASD) using NTI164. As autism remains the lead indication currently being pursued by Neurotech, the proposed patent protection aligns directly with the company's ongoing clinical development program.

Together, these patent applications are intended to strengthen the company's intellectual property position around its lead product candidate while supporting future commercial opportunities if development progresses successfully.

Patents Yet to Be Granted but Significant Milestone Achieved

Although the Notices of Allowance represent a positive regulatory milestone, the company clarified that the patents are not yet enforceable.

Formal patent rights will only come into effect after the patents have been officially granted following completion of standard administrative procedures by the USPTO.

Nevertheless, the Notices confirm that the patent office has determined both applications satisfy the legal requirements for patentability, representing an important step before formal issuance.

The company expects the two U.S. patents to be granted within the coming months.

Protection Through 2042 Could Support Long-Term Development

Intellectual property protection remains an important component of pharmaceutical product development, particularly for companies advancing proprietary therapies through clinical trials.

According to Neurotech, the expected patent grants would extend U.S. intellectual property protection for NTI164 through 2042, providing long-term coverage for the technology underlying the product candidate.

The company believes expanding its patent portfolio forms part of its broader strategy to enhance the value of its development pipeline while supporting future commercial opportunities.

NTI164 Continues to Progress Through Phase 3 Development

Alongside expanding its intellectual property portfolio, Neurotech continues progressing NTI164 through clinical development.

The company's lead therapy is currently in Phase 3 clinical development for the treatment of autism spectrum disorder in paediatric patients.

NTI164 is described as a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts together with selected minor cannabinoids. According to the company, earlier preclinical and clinical studies have demonstrated its potential to influence neuroinflammatory signalling, immune dysregulation and other biological pathways associated with neurodevelopmental disorders.

The Phase 3 program represents the next stage in evaluating NTI164 for children diagnosed with autism spectrum disorder.

Previous Clinical Studies Form the Foundation for Current Development

Neurotech highlighted that NTI164 has already been evaluated across several clinical studies.

The company previously completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in autism spectrum disorder, reporting clinically meaningful and statistically significant improvements across several clinically validated measures while also demonstrating an acceptable safety profile.

In addition, Neurotech has completed Phase I/II clinical studies involving children with autism spectrum disorder as well as patients with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS). The company has also undertaken clinical work involving Rett Syndrome.

Neurotech further noted that it has received human ethics committee clearance for its Phase 3 clinical study in autism spectrum disorder, supporting continued advancement of its lead program.

Management Highlights Focus on Expanding Global IP Portfolio

Commenting on the announcement, Chief Executive Officer and Managing Director Anthony Filippis said the Notices of Allowance represent continued execution of Neurotech's strategy to protect its core assets while expanding its global intellectual property portfolio.

Management noted that the USPTO's determination that both applications satisfy patentability requirements represents an important milestone within the company's U.S. intellectual property strategy for NTI164.

The company also indicated that, as the new financial year begins, it remains focused on achieving upcoming development milestones for NTI164 while seeking to address the need for additional treatment options for children diagnosed with autism spectrum disorder.

Why Today's Announcement Drew Market Attention

Biotechnology companies often attract investor attention when intellectual property milestones strengthen protection around lead development assets.

In Neurotech's case, today's announcement provides further progress on securing U.S. patent protection covering both neuroinflammation and autism spectrum disorder treatment methods associated with NTI164.

Although formal patent grants are still pending, the Notices of Allowance reduce uncertainty surrounding patent examination by confirming that the USPTO considers both applications to satisfy the requirements for issuance.

Combined with the ongoing Phase 3 clinical development program, the update appears to have contributed to the positive share price movement during today's trading session.

What This Means for Investors

Neurotech's latest update represents an important intellectual property development rather than a clinical trial outcome. The Notices of Allowance move two key U.S. patent applications closer to formal grant and, if issued, are expected to provide protection for NTI164 through 2042. The update also aligns with the company's broader strategy of advancing its Phase 3 autism program while strengthening global intellectual property around its lead therapeutic candidate. Investors are likely to continue monitoring both the formal grant of these patents and future clinical milestones for NTI164.

FAQs